8th Dec 2005 07:02
Skyepharma PLC08 December 2005 FOR IMMEDIATE RELEASE 8 December, 2005 SkyePharma PLC Strategic Review Update LONDON, ENGLAND, 8 December, 2005 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE)announced on 14 November, 2005 that the board of SkyePharma PLC ("SkyePharma" orthe "Company") (the "Board") had appointed Lehman Brothers to review all of thestrategic options for the Company in order to maximise value for allshareholders. Following this announcement the Company has received a number of expressions ofinterest, both with respect to individual assets owned by the Company as well aspotential cash offers for the Company as a whole. In the light of such interest,the Board has decided to allow a number of parties access to a data room tocommence due diligence on the Company. The intention of the Board is to swiftly ascertain whether these expressions ofinterest can be translated into firm proposals capable of being recommended toshareholders. However, there is no certainty that this process will result in achange to the present ownership structure of the Company. A further announcementwill be made when appropriate. For further information please contact: SkyePharma PLC +44 207 491 1777Michael Ashton, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court/ Rebecca Skye Dietrich +44 7710 328 560 Notes to Editors About SkyePharmaSkyePharma develops pharmaceutical products benefiting from world-leading drugdelivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. Lehman Brothers Europe Limited, which is regulated in the United Kingdom by theFinancial Services Authority, is acting for SkyePharma and no one else inrelation to the matters described in this announcement, and will not beresponsible to anyone other than SkyePharma for providing the protectionsafforded to customers of Lehman Brothers Europe Limited or for providing adviceon matters described in this announcement. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L